First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation
Status:
Unknown status
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
Eligible patients are administered with oral icotinib 125mg three times daily for two months,
in which responsive patients (partial response and stable disease) are randomized (1: 1: 1)
and receive icotinib plus concurrent radiotherapy, or chemotherapy plus concurrent
radiotherapy, or icotinib monotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University